arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

Galmed Pharmaceuticals Ltd.

GLMD

$4.58 0.00 (0.00%) at close

15 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Galmed Pharmaceuticals Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $19.7M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC None

FCF / Share $-1.46 ↗

Trailing P/E 1.9x

Price / Book 1.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 9, 2026.

15-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-10.31M

↓ -37.1% —

FCF / Share Free cash flow per share

$-1.46

↑ +76.8% —

Long-Term Debt Long-term obligations

$0.00

↓ -100.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗	FY 2015 Dec 31, 2015 20-F ↗	FY 2014 Dec 31, 2014 20-F ↗	FY 2013 Dec 31, 2013 20-F ↗	FY 2012 Dec 31, 2012 20-F ↗	FY 2011 Dec 31, 2011 20-F ↗
Revenue Growth YoY (%)	—	—	—	—	—	—	N/M	87.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+998%)	132.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1554%)	—	—	—	—	—	—
EPS Growth YoY (%)	-70.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-73.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	181.7% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	706.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-2.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-37.1% Weak ↓ Weak Declining Year-over-year change in net income	-8.8% Weak ↓ Weak Declining Year-over-year change in net income	61.3% Excellent ↑ Excellent Improving Year-over-year change in net income	45.0% Excellent ↑ Excellent Improving Year-over-year change in net income	-12.8% Weak ↑ Weak Improving Year-over-year change in net income	-40.6% Weak ↓ Weak Declining Year-over-year change in net income	-107.6% Weak ↓ Weak Declining Year-over-year change in net income	19.9% Good ↑ Good Improving Year-over-year change in net income	27.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-59.6% Weak ↑ Weak Improving Year-over-year change in net income	-16.7% Weak ↑ Weak Improving Year-over-year change in net income	47.9% Excellent Excellent Year-over-year change in net income	-455.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	76.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	76.2% Excellent Excellent Year-over-year change in free cash flow	-140.9% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—	—
EPS CAGR 3Y (%)	-39.2% Weak ↓ Weak Declining Compound annual EPS growth over 3 years	82.9% Excellent Excellent Compound annual EPS growth over 3 years	181.1% Excellent Excellent Compound annual EPS growth over 3 years	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗	FY 2015 Dec 31, 2015 20-F ↗	FY 2014 Dec 31, 2014 20-F ↗	FY 2013 Dec 31, 2013 20-F ↗	FY 2012 Dec 31, 2012 20-F ↗	FY 2011 Dec 31, 2011 20-F ↗
Profit Margin (%) (%)	—	—	—	—	—	—	—	-483.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4130%)	—	—	—	—	—	—	—
FCF Margin (%) (%)	—	—	—	—	—	—	—	-447.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—
FCF / Net Income (x)	0.61x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗	FY 2015 Dec 31, 2015 20-F ↗	FY 2014 Dec 31, 2014 20-F ↗	FY 2013 Dec 31, 2013 20-F ↗	FY 2012 Dec 31, 2012 20-F ↗	FY 2011 Dec 31, 2011 20-F ↗
Return on Invested Capital (%)	—	—	—	—	—	—	-25.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-9.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	—	—	—
Return on Capital (%) (%)	—	—	—	—	—	—	-29.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-11.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—	—	—
Return on Common Equity (%) (%)	-65.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-535%)	-46.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-407%)	-49.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-432%)	-133.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-987%)	-106.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-810%)	-65.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-534%)	-29.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-295%)	-11.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-175%)	-77.9% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-619%)	-153.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1120%)	-49.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-429%)	-29.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-293%)	—	159.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+961%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗	FY 2015 Dec 31, 2015 20-F ↗	FY 2014 Dec 31, 2014 20-F ↗	FY 2013 Dec 31, 2013 20-F ↗	FY 2012 Dec 31, 2012 20-F ↗	FY 2011 Dec 31, 2011 20-F ↗
Debt to Equity (x)	—	—	—	—	—	—	—	—	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.07x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-88%)	0.01x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-99%)	0.01x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-98%)	-0.22x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-137%)	—	—
Net Debt (USD)	$-3.98M	$-4.65M	$-2.86M	$-2.02M	$-2.88M	$-6.95M	$-15.93M	$-24.16M	$-13.02M	$-2.30M	$-3.98M	$-23.34M	$291.00K	$-718.00K	$-146.00K

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗	FY 2015 Dec 31, 2015 20-F ↗	FY 2014 Dec 31, 2014 20-F ↗	FY 2013 Dec 31, 2013 20-F ↗	FY 2012 Dec 31, 2012 20-F ↗	FY 2011 Dec 31, 2011 20-F ↗
Basic EPS, GAAP (USD)	$2.39	$8.08	$30.00	$10.65	$1.32	$1.35	—	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-1.46	$-6.32	$-26.59	$-11.04	—	—	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$2.40	$9.81	$24.19	$7.93	$1.22	$2.07	$3.30	$4.18	$1.09	$0.91	$1.94	$2.83	—	—	—
Tangible Book Value per Share (USD)	$2.40	$9.81	$24.19	$7.93	$1.22	$2.07	$3.30	$4.18	$1.09	$0.91	$1.94	$2.83	—	—	—
Basic Weighted Avg Shares (shares)	4.31M	930,822	230,795	1.68M	—	—	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗	FY 2015 Dec 31, 2015 20-F ↗	FY 2014 Dec 31, 2014 20-F ↗	FY 2013 Dec 31, 2013 20-F ↗	FY 2012 Dec 31, 2012 20-F ↗	FY 2011 Dec 31, 2011 20-F ↗
Working Capital (USD)	$15.78M	$13.95M	$10.49M	$11.63M	$30.18M	$43.80M	$69.50M	$87.70M	$15.30M	$11.15M	$20.84M	$31.03M	$-1.54M	—	—
LT Debt (USD)	—	—	—	—	—	—	—	—	$0.00	$796.00K	$177.00K	$400.00K	$428.00K	—	—
Total Equity (USD)	$15.78M	$16.33M	$13.88M	$13.42M	$30.50M	$44.15M	$69.85M	$87.89M	$15.79M	$11.07M	$21.55M	$31.41M	$-1.95M	$-1.98M	$-2.71M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗	FY 2015 Dec 31, 2015 20-F ↗	FY 2014 Dec 31, 2014 20-F ↗	FY 2013 Dec 31, 2013 20-F ↗	FY 2012 Dec 31, 2012 20-F ↗	FY 2011 Dec 31, 2011 20-F ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	$0.00	$2.04M	$1.08M	$467.00K	$0.00	—	—	—	—
Depreciation Expense (USD)	—	$80.00K	$30.00K	—	—	$39.00K	$35.00K	$387.00K	$239.00K	$169.00K	$50.00K	$9.00K	$4.00K	$5.00K	—
Net Income, GAAP (USD)	$-10.31M	$-7.52M	$-6.91M	$-17.87M	$-32.47M	$-28.77M	$-20.46M	$-9.86M	$-12.30M	$-16.95M	$-10.62M	$-9.10M	$-17.48M	$-3.15M	—
Operating Cash Flow (USD)	$-6.32M	$-5.88M	$-6.14M	$-18.50M	$-32.89M	$-26.29M	$-14.94M	$-9.02M	$-12.07M	$-12.13M	—	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 15 quarters

Galmed Pharmaceuticals Ltd.

Analytical Summary

15-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare GLMD with peers